{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:11:54Z","timestamp":1792566714340,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["12B2W24N"],"award-info":[{"award-number":["12B2W24N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007660","name":"University of Antwerp","doi-asserted-by":"publisher","award":["FFB210425"],"award-info":[{"award-number":["FFB210425"]}],"id":[{"id":"10.13039\/501100007660","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Foundation Against Cancer","doi-asserted-by":"publisher","award":["2025-034"],"award-info":[{"award-number":["2025-034"]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Fight against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201316","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:14:20Z","timestamp":1785996860000},"page":"201316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0216-9208","authenticated-orcid":false,"given":"Laura","family":"Gehrcken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Van den Eynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Wa","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tias","family":"Verhezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Faghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Joye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gils","family":"Roex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Campillo-Davo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe","family":"Elvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9365-0641","authenticated-orcid":false,"given":"Senada","family":"Koljenovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorrit","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-1407","authenticated-orcid":false,"given":"Geert","family":"Roeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-7352","authenticated-orcid":false,"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Lardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8085-2040","authenticated-orcid":false,"given":"Christophe","family":"Deben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5619-1913","authenticated-orcid":false,"given":"Jonas","family":"Van Audenaerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201316_bib1","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i43.111433","article-title":"Pancreatic cancer in 2025: Have we found a solution?","volume":"31","author":"Tonini","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omton.2026.201316_bib2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s12029-024-01054-2","article-title":"CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials","volume":"55","author":"Drougkas","year":"2024","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201316_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201316_bib5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib6","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201316_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201316_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886429","article-title":"Next Generation Natural Killer Cells for Cancer Immunotherapy","volume":"13","author":"Rossi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201316_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201316_bib11","article-title":"MSLN induced EMT, cancer stem cell traits and chemotherapy resistance of pancreatic cancer cells","volume":"10","author":"Hu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.omton.2026.201316_bib12","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201316_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/ijms.39012","article-title":"Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"17","author":"Le","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.omton.2026.201316_bib14","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: A New Target for Immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/biomedicines9040397","article-title":"Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors","volume":"9","author":"Weidemann","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2026.201316_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omton.2026.201316_bib17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201316_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: An emerging target in cancer immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omton.2026.201316_bib20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pan.2021.01.013","article-title":"Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential","volume":"21","author":"Nakamura","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.omton.2026.201316_bib21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-24-3128","article-title":"Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant\/Refractory High-Grade Ovarian Cancer (NCI Trial)","volume":"31","author":"Alqaisi","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib22","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-17-0613","article-title":"Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies","volume":"23","author":"Aftimos","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib23","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201316_bib24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201316_bib25","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/07357907.2025.2548603","article-title":"Tandem Dual CAR-T Cells Targeting HER2 and Mesothelin Enhance anti-Tumor Effects in Pancreatic Cancer","volume":"43","author":"Jiang","year":"2025","journal-title":"Cancer Invest."},{"key":"10.1016\/j.omton.2026.201316_bib26","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.ymthe.2020.07.017","article-title":"Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer","volume":"28","author":"Ko","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201316_bib27","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1126\/science.adv7378","article-title":"Sensitive CAR T cells redefine targetable CD70 expression in solid tumors","volume":"391","author":"Hanina","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201316_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2023.100098","article-title":"High expression of mesothelin in plasma and tissue is associated with poor prognosis and promotes invasion and metastasis in gastric cancer","volume":"7","author":"Saha","year":"2023","journal-title":"Adv. Cancer Biol. Metastasis"},{"key":"10.1016\/j.omton.2026.201316_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41389-020-00246-2","article-title":"Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation","volume":"9","author":"Coelho","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.omton.2026.201316_bib30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/ijc.30830","article-title":"Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM","volume":"141","author":"Ge","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/path.5361","article-title":"CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness","volume":"250","author":"Inaguma","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.omton.2026.201316_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bjc.2015.412","article-title":"Melanoma-expressed CD70 is involved in invasion and metastasis","volume":"114","author":"Pich","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101611","article-title":"Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201316_bib34","first-page":"4235","article-title":"High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosis","volume":"13","author":"Hagerty","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202407976","article-title":"Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models","volume":"12","author":"Cai","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omton.2026.201316_bib36","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib37","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody\u2013Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201316_bib38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/0008-5472.CAN-23-1542","article-title":"Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis","volume":"84","author":"Luckett","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib39","first-page":"A214","article-title":"203 A membrane-tethered IL-15\/IL-15 receptor fusion protein enhances the persistence and efficacy of CD70-targeted TRuC-T cells","volume":"9","author":"Ding","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib40","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1186\/s12967-024-05851-y","article-title":"Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer","volume":"22","author":"Torchiaro","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2026.201316_bib41","article-title":"Empowering pancreatic tumor homing with augmented anti-tumor potency of CXCR2-tethered CAR-NK cells","volume":"32","author":"Yoon","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201316_bib42","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK\/CD3\u03b6\/ZAP70 Signaling Axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201316_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13683","article-title":"Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity","volume":"57","author":"Wang","year":"2024","journal-title":"Cell Prolif."},{"key":"10.1016\/j.omton.2026.201316_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1675877","article-title":"2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity","volume":"16","author":"dos Santos","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib45","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/s43018-025-00940-3","article-title":"Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial","volume":"6","author":"Lei","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib46","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-022-03326-6","article-title":"Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells","volume":"20","author":"Roex","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omton.2026.201316_bib47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13046-026-03722-6","article-title":"Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity","volume":"45","author":"Freudenberg-Jahn","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-025-00618-7","article-title":"CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201316_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omton.2026.201316_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112523","article-title":"Chimeric antigen receptor NK-92 cell function is modulated by HLA class I expression of target cells","volume":"28","author":"Stransky","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.omton.2026.201316_bib51","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201316_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070966","article-title":"Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability (Running Title: Cryopreserved NK Cells Exhibit Antitumor Effect)","volume":"11","author":"Oh","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201316_bib53","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of CAR-NK cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201316_bib54","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201316_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013796","article-title":"Effective allogeneic natural killer cell therapy for pancreatic adenocarcinoma avails conserved activating receptors and evades HLA I-driven inhibition","volume":"14","author":"Lee","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib56","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3389\/fimmu.2019.01354","article-title":"Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-\u03b21 Deregulation and Disease Progression in Pancreatic Cancer","volume":"10","author":"Jun","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","article-title":"Metabolism of pancreatic cancer: paving the way to better anticancer strategies","volume":"19","author":"Qin","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the Combination Immunotherapy of Cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adt9932","article-title":"Robust differentiation of NK cells from MSLN.CAR-IL-15\u2013engineered human iPSCs with enhanced antitumor efficacy against solid tumors","volume":"11","author":"Jiang","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2026.201316_bib61","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201316_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omton.2026.201316_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1546172","article-title":"Tandem CAR-T cell therapy: recent advances and current challenges","volume":"16","author":"G\u00f3mez-Melero","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012822","article-title":"Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time","volume":"13","author":"Salas-Benito","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib65","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.omton.2026.201316_bib66","article-title":"Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV","volume":"2","author":"Naeimi Kararoudi","year":"2022","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.omton.2026.201316_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121910","article-title":"Application and Design of Switches Used in CAR","volume":"11","author":"G\u0142owacki","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omton.2026.201316_bib68","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00262-022-03340-z","article-title":"Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers","volume":"72","author":"Fiore","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201316_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/13510002.2026.2626181","article-title":"DRP1 depletion protects NK cells from hypoxia-induced dysfunction","volume":"31","author":"Verhezen","year":"2026","journal-title":"Redox Rep."},{"key":"10.1016\/j.omton.2026.201316_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.884648","article-title":"Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications","volume":"13","author":"Terr\u00e9n","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib71","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","article-title":"Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells","volume":"20","author":"Leong","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omton.2026.201316_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1507","article-title":"Optimisation of a primary human CAR-NK cell manufacturing pipeline","volume":"13","author":"Pfefferle","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.omton.2026.201316_bib73","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201316_bib74","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201316_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.omton.2026.201316_bib76","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201316_bib77","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41416-020-0934-3","article-title":"Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status","volume":"123","author":"Baysal","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201316_bib78","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41698-023-00480-y","article-title":"Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer","volume":"7","author":"Le Compte","year":"2023","journal-title":"NPJ Precis. Oncol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992600192X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992600192X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:35:23Z","timestamp":1790253323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032992600192X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S295032992600192X"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201316","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201316","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201316"}}